Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1530/EJE-20-1374 http://scihub22266oqcxt.onion/10.1530/EJE-20-1374 33449918!9494345!33449918     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Endocrinol 2021 ; 184 (3): 409-418 Nephropedia Template TP {{tp|p=33449918|t=2021. Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls |pdf=|usr=}}{{33449918}} gab.com Text Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls JO: Eur J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=33449918 #FOAvip OBJECTIVE: The pandemic of coronavirus disease (COVID-19) has rapidly spread globally and infected millions of people. The prevalence and prognostic impact of dysnatremia in COVID-19 is inconclusive. Therefore, we investigated the prevalence and outcome of dysnatremia in COVID-19. DESIGN: The prospective, observational, cohort study included consecutive patients with clinical suspicion of COVID-19 triaged to a Swiss Emergency Department between March and July 2020. METHODS: Collected data included clinical, laboratory and disease severity scoring parameters on admission. COVID-19 cases were identified based on a positive nasopharyngeal swab test for SARS-CoV-2, patients with a negative swab test served as controls. The primary analysis was to assess the prognostic impact of dysnatremia on 30-day mortality using a cox proportional hazard model. RESULTS: 172 (17%) cases with COVID-19 and 849 (83%) controls were included. Patients with COVID-19 showed a higher prevalence of hyponatremia compared to controls (28.1% vs 17.5%, P < 0.001); while comparable for hypernatremia (2.9% vs 2.1%, P = 0.34). In COVID-19 but not in controls, hyponatremia was associated with a higher 30-day mortality (HR: 1.4, 95% CI: 1.10-16.62, P = 0.05). In both groups, hypernatremia on admission was associated with higher 30-day mortality (COVID-19 - HR: 11.5, 95% CI: 5.00-26.43, P < 0.001; controls - HR: 5.3, 95% CI: 1.60-17.64, P = 0.006). In both groups, hyponatremia and hypernatremia were significantly associated with adverse outcome, for example, intensive care unit admission, longer hospitalization and mechanical ventilation. CONCLUSION: Our results underline the importance of dysnatremia as predictive marker in COVID-19. Treating physicians should be aware of appropriate treatment measures to be taken for patients with COVID-19 and dysnatremia. Twit Text FOAVip Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls ????Eur J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=33449918 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33449918 #FOAvip English Wikipedia <ref>{{Cite pmid|33449918}}</ref> Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls #MMPMID33449918 Atila C; Sailer CO; Bassetti S; Tschudin-Sutter S; Bingisser R; Siegemund M; Osswald S; Rentsch K; Rueegg M; Schaerli S; Kuster GM; Twerenbold R; Christ-Crain M Eur J Endocrinol 2021[Mar]; 184 (3): 409-418 PMID33449918show ga OBJECTIVE: The pandemic of coronavirus disease (COVID-19) has rapidly spread globally and infected millions of people. The prevalence and prognostic impact of dysnatremia in COVID-19 is inconclusive. Therefore, we investigated the prevalence and outcome of dysnatremia in COVID-19. DESIGN: The prospective, observational, cohort study included consecutive patients with clinical suspicion of COVID-19 triaged to a Swiss Emergency Department between March and July 2020. METHODS: Collected data included clinical, laboratory and disease severity scoring parameters on admission. COVID-19 cases were identified based on a positive nasopharyngeal swab test for SARS-CoV-2, patients with a negative swab test served as controls. The primary analysis was to assess the prognostic impact of dysnatremia on 30-day mortality using a cox proportional hazard model. RESULTS: 172 (17%) cases with COVID-19 and 849 (83%) controls were included. Patients with COVID-19 showed a higher prevalence of hyponatremia compared to controls (28.1% vs 17.5%, P < 0.001); while comparable for hypernatremia (2.9% vs 2.1%, P = 0.34). In COVID-19 but not in controls, hyponatremia was associated with a higher 30-day mortality (HR: 1.4, 95% CI: 1.10-16.62, P = 0.05). In both groups, hypernatremia on admission was associated with higher 30-day mortality (COVID-19 - HR: 11.5, 95% CI: 5.00-26.43, P < 0.001; controls - HR: 5.3, 95% CI: 1.60-17.64, P = 0.006). In both groups, hyponatremia and hypernatremia were significantly associated with adverse outcome, for example, intensive care unit admission, longer hospitalization and mechanical ventilation. CONCLUSION: Our results underline the importance of dysnatremia as predictive marker in COVID-19. Treating physicians should be aware of appropriate treatment measures to be taken for patients with COVID-19 and dysnatremia. |Adult[MESH] |Aged[MESH] |COVID-19/complications/*diagnosis/*epidemiology/therapy[MESH] |Case-Control Studies[MESH] |Cohort Studies[MESH] |Critical Care/statistics & numerical data[MESH] |Female[MESH] |Hospital Mortality[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Hypernatremia/complications/*diagnosis/*epidemiology/therapy[MESH] |Hyponatremia/complications/*diagnosis/*epidemiology/therapy[MESH] |Length of Stay/statistics & numerical data[MESH] |Male[MESH] |Middle Aged[MESH] |Mortality[MESH] |Pandemics[MESH] |Prevalence[MESH] |Prognosis[MESH] |Prospective Studies[MESH] |SARS-CoV-2[MESH] |Switzerland/epidemiology[MESH]Prevalence and outcome of dysnatremia in patients with COVID-19 compar(epmc).pdf DeepDyve Pubget Overpricing